Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
April 20, 2026
Fentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics
Fentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics
By identifying the molecular mechanisms that control BRM cell formation, the new study provides a clearer paradigm for understanding how long-term immunity is established in the respiratory tract.
Zhao is part of a team working on a potential solution: a novel wound dressing that uses materials created by human cells—without including the cells themselves.
New research from Binghamton University and Drexel University looks at a different, lesser-studied issue that also hurts patients and their quality of life: how Parkinson’s affects the human vascular system.
Soft electrodes designed to perfectly match a person’s brain surface may help advance neural interfaces for neurodegenerative disease monitoring and treatment, according to a new study led by Penn State researchers.
A UCLA-led research team has now developed a microneedle sensor platform designed to address that problem through continuous, minimally invasive monitoring in skin.
We asked if it would be possible to first implant a small-scale liver construct and then drive it to expand in the body following its engraftment.
MONTREAL, April 17, 2026 /PRNewswire/ — Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY® injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent (GBCA), for use in contrast-enhanced magnetic resonance imaging (CE-MRI).
PITTSBURGH, April 17, 2026 /PRNewswire/ — Xodus Medical today announced the launch of the Hot Pink Pad®, a next-generation patient temperature management and positioning system designed to improve surgical outcomes, enhance patient safety, and streamline operating room workflows.
MADRID, April 17, 2026 /PRNewswire/ — Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS® System, the first imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac electrical activity in real-time.